Shaji Kumar, MD

Shaji Kumar, MD, Mayo Clinic, explores the potential for earlier intervention and curative approaches in multiple myeloma, and explains how harnessing a patient's immune system through therapies like T-cell redirection could lead to better disease control, significantly extending progression-free survival and ultimately improving patient outcomes.

Shaji Kumar, MD, Mayo Clinic, touches on the complexities of the drug approval process and examines how manufacturing challenges can delay FDA approval. He also returns to the guidelines update and their call to tailor treatment intensity overall and ensure equitable care for Black or African American individuals.

Shaji Kumar, MD, Mayo Clinic, highlights linvoseltamab’s dosing regimen, adverse effect profile, and management strategies. He speaks in particular about cytokine release syndrome, which although common, is typically mild and of short duration, and of proactive prophylaxis to mitigate the risk of severe infection.

Shaji Kumar, MD, Mayo Clinic, focuses on the selection, outcomes, and real-world impact of BCMA-targeted bispecific antibodies for multiple myeloma. He emphasizes the factors influencing choice of linvoseltamab, teclistamab, and elranatamab; addresses the impressive results from the LINKER-MM1 trial, which served as the basis for linvoseltamab’s FDA approval; and speaks to linvoseltamab’s new inclusion as a preferred agent in NCCN Guidelines.

Shaji Kumar, MD, Mayo Clinic, discusses the July approval of linvoseltamab, a new bispecific antibody for relapsed myeloma, and how it expands treatment options for patients. He also emphasizes the unique characteristics of linvoseltamab, such as its intravenous administration and flexible dosing schedule.

A panelist discusses how clinicians are navigating the evolving landscape of multiple myeloma treatment, from considering early intervention in high-risk smoldering cases to personalizing initial therapy choices between triplet and quadruplet regimens.